Edition:
India

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

349.50DKK
19 Jan 2018
Change (% chg)

kr.7.50 (+2.19%)
Prev Close
kr.342.00
Open
kr.347.80
Day's High
kr.352.25
Day's Low
kr.346.10
Volume
3,603,486
Avg. Vol
2,884,378
52-wk High
kr.352.25
52-wk Low
kr.225.60

Latest Key Developments (Source: Significant Developments)

Ozempic Approved In Canada For The Treatment Of Adults With Type 2 Diabetes
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Novo Nordisk ::OZEMPIC® APPROVED IN CANADA FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES.SAYS ‍OZEMPIC DEMONSTRATED CLINICALLY MEANINGFUL IMPROVEMENTS IN BLOOD SUGAR AND BODY WEIGHT VERSUS COMPARATORS​.  Full Article

Ablynx's Board Says Takeover Proposal From Novo Nordisk Undervalues Company
Monday, 8 Jan 2018 

Jan 8 (Reuters) - ABLYNX NV ::BOARD UNANIMOUSLY CONCLUDED THAT PROPOSAL FUNDAMENTALLY UNDERVALUES ABLYNX AND ITS STRONG PROSPECTS FOR CONTINUED GROWTH AND VALUE CREATION.TODAY CONFIRMED THAT ON DEC 22, 2017 IT RECEIVED UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK A/S.J.P. MORGAN IS SERVING AS FINANCIAL ADVISOR TO ABLYNX.ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS.CO LONG-TERM STRATEGIC PLAN OF BECOMING FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY."BOARD SEES NO MERIT IN CEDING CONTROL OF ITS ASSETS WITHOUT FULL UPFRONT VALUE RECOGNITION FOR SHAREHOLDERS" - CEO.  Full Article

Novo Nordisk CFO Says Not Our Understanding That Any Other Bidder Is Pursuing Ablynx
Monday, 8 Jan 2018 

Jan 8 (Reuters) - NOVO NORDISK NOVOB.CO CHIEF FINANCIAL OFFICER JESPER BRANDGAARD SAID ON A CONFERENCE CALL IN RELATION TO BID FOR ABLYNX ::"IN TERMS OF COUNTER PROPOSALS IT IS NOT OUR UNDERSTANDING THAT ANY OTHER BIDDER IS PURSUING THE TARGET" nFWN1P3016.  Full Article

Novo Nordisk has proposed to buy Ablynx for up to 30.50 euros per share in cash
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Novo Nordisk ::HAS PROPOSED TO BUY ABLYNX FOR UP TO EUR 30.50 PER SHARE IN CASH, CONSISTING OF EUR 28.00 UPFRONT AND EUR 2.50 IN CONTINGENT VALUE RIGHTS​.‍PROPOSAL IMPLIES A TOTAL EQUITY VALUATION OF APPROXIMATELY EUR 2.6 BILLION FOR ABLYNX​.PROPOSAL IS SECOND PROPOSAL THAT CO HAS MADE TO ABLYNX'S BOARD AND REPRESENTS UP TO APPROXIMATELY A 14% INCREASE OVER FIRST PROPOSAL​.CO "REGRETS" THAT BOARD OF ABLYNX HAS SO FAR DECLINED TO ENGAGE IN ANY DISCUSSIONS, DESPITE PROPOSALS WHICH HAVE BEEN PUT FORWARD​.PROPOSAL ALSO CONSISTS OF ONE CONTINGENT VALUE RIGHT WITH TOTAL POTENTIAL CASH PAYMENTS OVER TIME OF UP TO EUR 2.50 PER SHARE​.  Full Article

EU Medicines Agency Recommendations For December 2017 ‍​
Friday, 15 Dec 2017 

Dec 15 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDATIONS FOR DECEMBER 2017 ‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF NOVO NORDISK'S ONCE-WEEKLY DIABETES DRUG SEMAGLUTIDE‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF KYOWA HAKKO KIRIN DRUG FOR GENETIC BLOOD DISORDER XLH BUROSUMAB.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TIGENIX'S STEM CELLS TREATMENT FOR PERIANAL FISTULAS ALOFISEL.  Full Article

reMYND Enters Into License Agreement with Novo Nordisk​
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - reMYND::REMYND-UNDER AGREEMENT,CO COULD RECEIVE UP TO 350 MILLION EUROS IN RESEARCH AND MILESTONE PAYMENTS,PLUS ROYALTIES ON RESULTING NET SALES.REMYND ENTERS INTO LICENSE AGREEMENT TO FURTHER DEVELOP NOVEL TREATMENTS IMPROVING BETA-CELL HEALTH AND INSULIN SIGNALLING WITH NOVO NORDISK​.  Full Article

Prime Therapeutics Says Co, Novo Nordisk To Establish Value-Based Contract For Type 2 Diabetes Drug Victoza
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Novo Nordisk A/S ::PRIME THERAPEUTICS - CO, NOVO NORDISK TO ESTABLISH A VALUE-BASED CONTRACT FOR TYPE 2 DIABETES DRUG, VICTOZA.  Full Article

Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC::STILL EXPECTS TO LAUNCH OZEMPIC DIABETES DRUG IN JAPAN DURING THE FIRST HALF OF NEXT YEAR."WHEN IT COMES TO THE JAPANESE SITUATION WE ARE STILL EXPECTING TO MEET UP WITH THE COMMITTEE DURING THE COURSE OF JANUARY AND THEN BE ABLE TO WRAP UP THE LABEL, SO WE ARE EXPECTING ... TO LAUNCH DURING THE COURSE OF THE FIRST OF HALF OF NEXT YEAR ALSO IN JAPAN"."IN EUROPE WE SHOULD HOPE THAT THE ENDORSEMENT IS GIVEN BY THE CHMP (COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE) DURING THE MONTH OF DECEMBER".THE U.S. FOOD AND DRUG ADMINISTRATION ON TUESDAY APPROVED NOVO'S DIABETES DRUG OZEMPIC, SETTING THE STAGE FOR A HEATED BATTLE WITH ELI LILLY & CO'S <<>> TRULICITY nL1N1O51MY.  Full Article

Novo' Xultophy reported as better option than basal-bolus insulin therapy to manage type 2 diabetes
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - NOVO NORDISK A/S ::XULTOPHY REPORTED A BETTER OPTION THAN BASAL-BOLUS INSULIN THERAPY TO MANAGE TYPE 2 DIABETES BY PARTICIPANTS IN THE DUAL VII CLINICAL TRIAL.THIS WAS REPORTED BY PEOPLE WITH TYPE 2 DIABETES WHOSE BLOOD SUGAR WAS NOT CONTROLLED ON INSULIN GLARGINE U100 WITH METFORMIN, AND WHO COMPLETED QUALITY-OF-LIFE QUESTIONNAIRES AS PART OF THE DUAL VII CLINICAL TRIAL.MORE PEOPLE PREFERRED TO STAY ON XULTOPHY COMPARED WITH BASAL-BOLUS THERAPY (84.5 PCT VERSUS 68.1 PCT).RESULTS WERE PRESENTED AT THE 2017 INTERNATIONAL DIABETES FEDERATION CONGRESS IN ABU DHABI, UAE..  Full Article

Novo Nordisk's Xultophy offers greater weight reductions than Iglarlixi
Monday, 4 Dec 2017 

Dec 4 (Reuters) - NOVO NORDISK SAYS::XULTOPHY CAN DELIVER GREATER REDUCTIONS IN THE OVERALL BLOOD SUGAR LEVELS AND WEIGHT FOR PEOPLE WITH TYPE 2 DIABETES WHO ARE UNCONTROLLED ON BASAL INSULIN, COMPARED TO IGLARLIXI.NEW FINDINGS ARE FROM AN INDIRECT COMPARISON BETWEEN XULTOPHY AND IGLARLIXI PUBLISHED IN THE JOURNAL OF MEDICAL ECONOMICS .THE ANALYSIS IS BASED ON PUBLISHED DATA FROM INDIVIDUAL CLINICAL TRIALS WHICH INVOLVED OVER 700 ADULTS LIVING WITH TYPE 2 DIABETES.PEOPLE WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN ACHIEVED A 0.44 PCT GREATER REDUCTION OF THEIR OVERALL BLOOD SUGAR LEVELS (HBA(1C)), AND A 1.42 KG GREATER WEIGHT LOSS WHEN TREATED WITH XULTOPHY, COMPARED TO THOSE TREATED WITH IGLARLIXI, AT SIMILAR DOSES OF INSULIN. .  Full Article

UPDATE 1-Largest Ablynx investor would consider improved Novo Nordisk bid

BRUSSELS, Jan 18 The largest shareholder in Belgian biotech group Ablynx regards the 2.6 billion euro ($3.2 billion) offer made by Denmark's Novo Nordisk as too low but would be willing to consider a higher figure.